SupplementsProactive HealthWomens HealthCaronositol FertilityCaronositol Fertility Clinical Studies

Caronositol Fertility Research Studies

Caronositol Fertility® is a patented combination of Myo-inositol and D-Chiro inositol (3.6:1 ratio) studied for its role in fertility in women with fertility challenges related to Polycystic ovary syndrome (PCOS).

Clinical research suggests it improves the pregnancy rates and reduces the risk of Ovarian hyperstimulation syndrome (OHSS) in women with PCOS undergoing Intracytoplasmic sperm injection (ICSI) and improves oocyte cytoplasm quality in women with PCOS undergoing ICSI, as it has been shown to be effective in regularising menstrual cycles and improving insulin resistance.

Comparison of the effect of two combinations of myo-inositol and D-chiro-inositol in women with polycystic ovary syndrome undergoing ICSI: a randomised controlled trial

The purpose of this study was to evaluate the effect of two doses of D-chiro-inositol (DCI) in combination with Myo-inositol (MYO) in women with PCOS undergoing ICSI. No differences were found at baseline. The pregnancy and live birth rates were significantly higher in the Caronositol Fertility Group (CFG) and the risk of OHSS was lower. The combination of MYO-DCI at high doses of DCI improves the pregnancy rates and reduces the risk of OHSS in women with PCOS undergoing ICSI.

Read study

 

High dose of d-chiro-inositol improves oocyte quality in women with polycystic ovary syndrome undergoing ICSI: a randomised controlled trial

The aim of this study was to evaluate the effect of two doses of DCI in combination with MYO on the oocyte quality (OQ) of women with PCOS. According to a multivariate analysis the combination of MYO with high doses of DCI improved oocyte cytoplasm quality in women with PCOS undergoing ICSI. Zona pellucida, plasma membrane, cytoplasm and sperm reception were also improved.

Read Study

 

Management of polycystic ovary syndrome among Indian women using myo‐inositol and D-chiro-inositol

Myo-Inositol and D-chiro-inositol (MI-DCI) are used in the treatment of PCOS due to their insulin-sensitising actions and an evaluation was conducted in Indian women. Treatment with MI-DCI resulted in significant improvement in insulin levels, HOMA-IR score, Fasting plasma glucose (FPG), post-prandial plasma glucose (PPG) and lipid profile. The therapy restored menstruation and spontaneous ovulation and significantly attenuated the LH/FSH ratio.

Read Study

 

Efficacy of myo-inositol and d-chiro-inositol combination on menstrual cycle regulation and improving insulin resistance in young women with polycystic ovary syndrome: A randomised open-label study

The objective of the study was to compare the effect of myo-inositol and d-chiro-inositol in combination (MI + DCI) with combined hormonal contraceptive (CHC) on menstrual cycle regulation in young Indian women with PCOS. Myo-inositol and d-chiro-inositol in combination (3.6:1 ratio) are effective in regularsing menstrual cycles and improving insulin resistance.

Read study

LET’S DRIVE IMPACT TOGETHER

We are here to be your most valued partner – to pioneer, problem-solve and bring better nutrition to billions. Through the ingenuity of our people, our groundbreaking technologies can influence real change in the world.

Not just for you, our customer – but for all people, society and the planet.

Get in touch

Contact us today to explore collaboration opportunities or to learn more about our solutions.

This website is intended to provide business-to-business information. The information and statements herein are for example only and products and claims may not be approved in your region. The information and statements herein must be reviewed for compliance with applicable local laws. Please check with your local account representative to inquire about market clearance and claims approved for your region.

Nothing in this web site is intended to be an offer which is capable of acceptance and/or inducement of any kind. Descriptions of, or references or access to other publications within the web site do not imply endorsement of those publications. This web site could contain technical inaccuracies, and changes to the information contained herein may be made at any time without notice.

Kerry Group P.L.C. (including its associate and subsidiary companies) neither makes nor gives any warranty of any kind with respect to any subject matter or information included in, or for the completeness or accuracy, of this web site. Kerry Group P.L.C. is not responsible for any actions (or lack thereof) taken as a result of relying on or in any way using information contained in this website and in no event shall it be liable for any damages resulting from reliance on or use for any purpose of this information. Without limiting the above, Kerry Group P.L.C. shall have no responsibility for any act or omission of any other contributor.